Cerebain Biotech

Existing treatments cannot halt disease progression or extend life expectancy in a meaningful way. Cerebain's novel device-based approach is supported by research and patient outcomes. Clinical evidence supports the company’s methodology, indicating that omentum stimulation can improve cognitive function in dementia patients, including those with Alzheimer's disease. The minimally invasive, one-time device implantation will address the highly invasive challenges associated with prior omentum stimulation procedures. The patent-pending technology has broad applicability. Recent scientific breakthroughs in the potential identification of gene-specific proteins before symptom onset can complement our work.